The targeting of agmatine-liganded mitomycin C to an enzyme on the surface of tumour cells.
Tumour cells possess a cell surface protease referred to as guanidinobenzoatase (GB). We have synthesised a liganded form of mitomycin C which we refer to as MMC*. This MMC* has the fluorescent properties of mitomycin C and the additional ability to be directed to the active centre of GB by the agmatine moiety of the ligand. We have demonstrated the selective delivery of MMC* to the cell surface of tumour cells possessing active GB by fluorescent microscopy and competition experiments with molecules known to bind to the active centre of GB. The MMC* has a high affinity for tumour cell surface GB and we hope it may have potential in the selective delivery of mitomycin C in the chemotherapy of tumours in vivo.